ac271c9e-4219-4880-ad89-0df6d5df0bb4
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 83
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- WNT_BETA_CATENIN_SIGNALING+0.330
- HEDGEHOG_SIGNALING+0.300
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.270
- ANGIOGENESIS+0.240
- APICAL_SURFACE+0.210
- FATTY_ACID_METABOLISM+0.210
- BILE_ACID_METABOLISM+0.200
- P53_PATHWAY+0.200
- NOTCH_SIGNALING+0.180
- PEROXISOME+0.180
Top 10 suppressed
- E2F_TARGETS-0.460
- IL6_JAK_STAT3_SIGNALING-0.440
- G2M_CHECKPOINT-0.400
- INTERFERON_ALPHA_RESPONSE-0.400
- INTERFERON_GAMMA_RESPONSE-0.390
- INFLAMMATORY_RESPONSE-0.350
- ALLOGRAFT_REJECTION-0.330
- PROTEIN_SECRETION-0.320
- UNFOLDED_PROTEIN_RESPONSE-0.320
- COMPLEMENT-0.290
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR8518125 | — | F | 0.853 |
| 2 | GSM5359429 | — | — | 0.810 |
| 3 | TCGA-IQ-7631-01A-11R-2081-07 | — | — | 0.808 |
| 4 | TCGA-A2-A04N-01A-11R-A115-07 | — | A | 0.780 |
| 5 | TCGA-D8-A3Z6-01A-11R-A239-07 | — | A | 0.771 |
| 6 | SRR8613754 | — | F | 0.769 |
| 7 | ULC0515T_S15 | — | cohortA1 | 0.755 |
| 8 | aMVAC.P_003_TURBT_S220 | — | — | 0.755 |
| 9 | TCGA-AN-A0FS-01A-11R-A034-07 | — | A | 0.755 |
| 10 | TCGA-B6-A1KI-01A-11R-A14M-07 | — | B | 0.751 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 22 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| WNT_BETA_CATENIN_SIGNALING | 0.330 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.300 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.270 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.240 | Remibrutinib | — uncovered |
| APICAL_SURFACE | 0.210 | Temsirolimus | — uncovered |
| FATTY_ACID_METABOLISM | 0.210 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.200 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.200 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.180 | Inavolisib | — uncovered |
| PEROXISOME | 0.180 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.180 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.170 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.140 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.110 | Inavolisib | — uncovered |
| APOPTOSIS | 0.090 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.090 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.090 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.080 | Remibrutinib | — uncovered |
| ANDROGEN_RESPONSE | 0.070 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.070 | Idelalisib | — uncovered |